Virbac to take a leading position in Japan through the acquisition of Sasaeah
06 Marzo 2024 - 8:20AM
Virbac to take a leading position in Japan through the acquisition
of Sasaeah
| |
|
Virbac announces that it has signed a definitive agreement
with ORIX Corporation for the acquisition of its animal health
subsidiary Sasaeah for an enterprise value of approximately €280
million. |
Formed through the combination of two legacy
animal health providers (Fujita Pharmaceutical Co. Ltd. and Kyoto
Biken Laboratories Inc.) under the stewardship of ORIX Corporation,
Sasaeah generates annual revenues of about €75 million, of which
50% from vaccines. With strong footholds in Japan, Sasaeah
develops, manufactures and markets a large portfolio of veterinary
products targeting both farm animals and companion animals.
Upon completion, this strategic acquisition will
bring to Virbac a leadership position in the farm animal vaccines
market in Japan, notably in the cattle segment, and a large
portfolio of pharmaceutical products for all the major species.
Virbac will benefit from Sasaeah’s local manufacturing sites in
Japan and in Vietnam, its R&D capabilities as well as more than
500 passionate and skilled employees. Virbac will be propelled as a
leading animal health player in Japan, with an opportunity to
leverage these capabilities across Asia.
Sébastien Huron, chief executive officer Virbac
group: “Japan is a key market in the global animal health industry.
This acquisition aligns seamlessly with our company's vision for
2030, emphasizing geographic expansion in major markets, the growth
of our vaccines segment and the reinforcement of our key species.
We are deeply honored to welcome the talented Sasaeah team to our
global Virbac family. Together, we look forward to shaping the
future of animal health in Japan.”
Seiichi Miyake, managing executive officer of
ORIX Corporation, added: “After investing in Kyoto Biken
Laboratories and Fujita Pharmaceutical, ORIX successfully
integrated the capabilities of both companies to establish Sasaeah
as one of Japan's leading animal health groups. ORIX looks forward
to further improvements of Sasaeah’s product quality and supply
capability which will benefit from Virbac's world-class R&D,
manufacturing and quality competences. ORIX believes that the
combination of Sasaeah and Virbac will positively contribute to the
development of veterinary medicine."
Completion of the transaction is not subject to
any regulatory approval; it is therefore expected to close by the
beginning of April 2024.
Nomura acted as financial advisor to Virbac in
this transaction and Hogan Lovells acted as its legal advisor.
Press contacts - Agence
Libremullenlowe
|
Keïsha Tema -
k.tema@libremullenlowe.fr - + 33 7 63 18
59 03Anne Da Silva Passos -
a.dasilvapassos@libremullenlowe.fr - +33 7
60 53 99 28 |
- Virbac press release,Sasaeah_March 6 2024
Grafico Azioni Virbac (EU:VIRP)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Virbac (EU:VIRP)
Storico
Da Gen 2024 a Gen 2025
